There is a paradox at the heart of pharmaceutical communications. The sector invests more in content production than almost any other industry. The science is credible, the evidence is genuine, and the intent — to inform, to educate, to build trust — is sound. And yet, page after page, across company after company, that content fails to reach the people it is meant for. Not because it is wrong. Because it is not written for them.
The Healthcare Monitor Pharmaceuticals 2026 identifies audience misalignment as one of the most consistent and consequential weaknesses across the ten companies it examines. The problem is structural: content is created at the corporate level, where the primary frame of reference is often regulatory or investor-facing, and then served to patients, caregivers, and healthcare professionals who need fundamentally different things from it.
5 Gaps That Illustrate the Pattern
The report documents five specific audience targeting failures, each drawn from observed content across the ten companies. Together, they illuminate a common underlying dynamic: a single page attempting to serve two or three audiences simultaneously, satisfying none of them fully.
Roche: clinical science served to patients
Roche’s diagnostic and precision medicine content is scientifically strong — but significant portions of it rely on jargon and mechanism-of-action framing that is calibrated for clinicians, not for the patients listed as a primary target audience. A diagram of a testing workflow means something very different to an oncologist and to a patient who has just received a diagnosis. The content exists; the translation does not.
Novartis: investor language in oncology storytelling
Novartis oncology content frequently uses portfolio language — ‘asset’, ‘pipeline’, ‘diversified risk’ — in material that also targets patients. These terms reassure institutional investors and analysts. They do not help a patient formulate the right questions for their next oncologist appointment. The core message is sound; the vocabulary is wrong for half the intended audience.
GSK: population-level vaccination content without personal action cues
GSK’s vaccination content excels at the policy level — coverage statistics, population benefit, epidemiological modelling. For policymakers and health system planners, this is exactly the right level of detail. For a caregiver wondering whether their child or elderly parent should be vaccinated, and when, and where, the same content provides no actionable guidance. The call to action is missing.
Johnson & Johnson: tone mismatches across J&J’s combined medical device and pharmaceutical portfolio
J&J’s corporate hubs merge medical technology and pharmaceutical content in ways that create jarring tonal shifts — moving from lifestyle-adjacent consumer language to clinical device specifications within a single content journey. Neither patients nor healthcare professionals receive a coherent experience, because the content is optimized for neither.
Pfizer: B2B partnership announcements published to general audiences
Pfizer’s partnership and collaboration announcements are written for a business audience — platforms, ecosystems, co-development terms — and then published on channels where patient audiences are also present. A patient reading that a collaboration ‘leverages a differentiated platform’ does not know whether this changes anything about their treatment options. The announcement is accurate; the translation is absent.
“These five gaps have a common thread: a single page attempts to serve two purposes for multiple target groups. The core message is correct, but the word choice, examples, and calls to action are not specifically tailored to each audience.”
The Localization Dimension: Beyond Language
Localization in pharmaceutical communications is frequently understood as a translation challenge — adapting content from English into local languages. The HC Monitor analysis expands this frame significantly. True localization encompasses not just linguistic adaptation but audience-specific calibration: adjusting reading level, example selection, evidence framing, and calls to action for each target group in each market.
The AbbVie case study is instructive here. AbbVie’s web estate spans ten national markets — Argentina, Brazil, China, France, Germany, India, Japan, Spain, the UK, and the US — each with its own local CMS implementation, content governance practices, and template management. The global baseline may be strong; the variance between markets can be significant. A website’s performance is, as the report notes, only as consistent as its weakest local implementation.
This is not a problem unique to AbbVie. Any pharmaceutical company operating across multiple markets faces the same structural tension: central brand consistency versus local content relevance. The companies that resolve it most effectively tend to do so through modular content architectures — approved core messages with market-specific audience layers — rather than through either full centralization or full localization.
Practical Solutions That Do Not Require Rebuilding Everything
The report offers four practical mechanisms for closing audience targeting gaps without requiring fundamental content redesign:
- Modular text blocks: a single approved core message with separate blocks for patients, healthcare professionals, investors, and policymakers — each block adapted in vocabulary and call to action, but all drawing from the same approved evidence base.
- Audience-specific templates: franchise templates with fixed sections for each target group, so that no page can go live without addressing the core question each audience is actually asking.
- One primary call to action per audience: defining in advance what each target group should do next, and building the content pathway around that action rather than around the product or therapy area.
- Readability segmentation: setting explicit readability standards for patient-facing content (lower complexity, shorter sentences) versus clinician-facing or investor-facing content, and measuring compliance quarterly.
These are editorial and structural solutions, not technological ones. They require investment in governance and internal process, not necessarily in new platforms or tools. The constraint is not capability — it is discipline.
The broader lesson for pharmaceutical communicators is that audience fit is a quality dimension, not a nice-to-have. In a sector where the cost of miscommunication can be measured in clinical outcomes, regulatory scrutiny, or reputational damage, content that reaches the right person with the right message at the right level of complexity is not a communications aspiration. It is a professional standard.
